Shanghai, China
MindRank AI is an innovative AI-driven biotechnology company established in 2021, with a dual presence in China and the UK. Specializing in "undruggable" targets, it has rapidly assembled a team of 35 scientists, including members of the British Royal Society and award-winning experts from pharmaceutical R&D.
The company stands out for its successful development and transfer of a small molecule Preclinical Candidate (allosteric inhibitor) to a listed biotechnology firm just months after starting operations. Furthermore, their proprietary AI-driven drug discovery platform enabled them to advance a Class B GPCR into IND-enabling studies by January 2022, reflecting a swift and robust R&D trajectory.
MindRank AI's cutting-edge publications, including features in prestigious journals such as Nature Biomedical Engineering and Nature Machine Intelligence, underscore its scientific credibility and potential as a promising partner for investors keen on leveraging AI innovations in biotechnology.
